GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - VAXCYTE INC

Financial Performance:

• Completed a $1.0 billion financing round (equity and convertible debt) recently, bringing pro forma cash on the balance sheet to approximately $3.4 billion as of September.
• The company remains well-financed to advance all pipeline programs and fully fund the expected commercial launch of Vax31 in adults.
• Specific revenue, earnings, or margin figures were not disclosed as the company is pre-commercialization with no product sales reported.

Guidance and Future Outlook:

• Anticipates filing a Biologics License Application (BLA) for Vax31 in adults in the first half of 2028.
• Vax31 adult program is anchored by Phase 3 "Opus 1" data exceeding expectations, with "Opus 2" (concomitant flu use) and "Opus 3" (revaccination) data expected in the first half of next year.
• Infant Vax31 Phase 2 data (primary series and booster) expected by the end of the first half of next year, with a preference for concurrent unblinding and disclosure of both datasets.
• Market projections for the global Vax31 target market (adults and infants) are forecast to grow from ~$8.5 billion today to ~$12 billion over the next several years, driven primarily by adult segment growth.
• Long-term commercial strategy includes targeting revaccination for prior PCV recipients and expanding adult recommendations globally as budget and population access increase.

Business Segments and Product Lines:

• Vax31 (Adult): 31-valent pneumococcal conjugate vaccine; Phase 3 data showed 11/11 serotypes met thresholds (covering all PCV20/21 + 31), with 9/9 and 8/8 subsets also positive, demonstrating superiority over PCV20 for three non-covered plus cross-reactive serotypes.
• Vax31 (Infant): 31-valent program fully enrolled; Phase 2 utilizes dose-ranging (low, mid, high, and ultra-high 4.4 mcg) based on prior 24-valent data showing dose-dependent immune response improvements without carrier suppression.
• VaxA1 (Group A Strep): Advanced to Phase 1 Stage 2 in adults (focusing on safety/tolerability) to gather data for a Phase 2 efficacy study in school-aged children; leverages platform technology targeting multiple virulence factors.
• Technology Platform: Proprietary technology addresses limitations of conventional vaccines, enabling broader serotype coverage (31 vs. 20/21) while maintaining immunogenicity.

Market and Competitive Landscape:

• Competitive Gap: Addresses gaps in PCV20/21 (Capvaxiv) which miss key serotypes (4 and 19F) that are currently rebounding in the US; Vax31 aims to offer a "one-stop" solution covering 95% of invasive disease and 30-35% incremental coverage over PCV20.
• Market Dynamics: Adult market is the primary growth driver; pediatric market is flat; adult-to-pediatric ratio expected to shift from 33/67 to roughly 50/50.
• Regulatory Environment: FDA has set stricter immunogenicity thresholds to combat "immunologic creep" (20-25% decrease in response with each new valency); Vax31 claims to meet these stringent standards without observed creep.
• Competitive Moat: High hurdles for future competitors to achieve approval for >31 valent vaccines due to FDA's increasing stringency regarding immunogenicity breadth.

Risks and Challenges:

• Regulatory Complexity: BLA submission requires demonstrating manufacturing consistency across 31 serotypes (3 ECRIMs and 3 DPs), a substantial volume of work requiring multi-batch consistency validation.
• Clinical Execution: Reliance on upcoming Phase 2 infant data to confirm non-inferiority (targeting ~0.667 threshold) and robust immune responses across all 31 serotypes.
• Market Competition: Continued competition from existing PCVs and potential future entrants, though Vax31 aims to differentiate via breadth of coverage.

Management Commentary and Tone:

• Tone: Highly confident and optimistic; management repeatedly states results "exceeded expectations" and they are "thrilled" with the data profile.
• Strategic Confidence: Emphasizes the company is "well-financed" to launch and that the 2028 BLA timeline is driven by the technical complexity of the submission rather than commercial readiness delays.
• Differentiation: Stresses that the combination of superior immunogenicity and broad serotype coverage creates a significant competitive advantage and simplifies the value proposition for healthcare providers.

Analyst Questions and Answers:

• Q: How do the results impact future competitors? A: Meeting the stricter FDA thresholds makes it significantly harder for future broader vaccines to gain approval.
• Q: What is the incremental coverage of Vax31? A: ~30-35% over PCV20 and ~15% over PCV21, covering 95% of invasive disease.
• Q: Why was the BLA submission delayed to H1 2028? A: To accommodate the extensive work required for manufacturing consistency studies (31 serotypes x 3 batches) and regulatory submission, not a lack of commercial readiness.
• Q: How is the infant program designed? A: 4 doses in a dose-ranging study; primary readout will compare antibody levels (threshold >0.35 and non-inferiority) against PCV20, with a focus on the 4.4 mcg dose arm showing improved response.
• Q: What are the opportunities for VaxA1? A: Targets Group A Strep (GAS), a market with 600k+ deaths and high antibiotic usage; potential for a smaller efficacy study in children due to high attack rates.

Other Key Points:

• Manufacturing Scale: The company is proactively building inventory and has already produced significant batches to support the upcoming commercial launch and consistency studies.
• Unblinding Strategy: Management leans toward unblinding and disclosing both infant primary and booster data concurrently, though the option to do them sequentially remains.
• Global Expansion: International markets (ex-US) are expected to grow as countries expand adult vaccination programs from strict 65+ criteria to broader 50+ recommendations similar to the US.
• VaxA1 Potential: Projected as a "blockbuster opportunity" due to the high disease burden and ability to conduct efficient Phase 2 studies in school-aged children.